IP
IPHA.US Innate Pharma
- Market cap
- USD 154M
- P/E
- -
- P/B
- 30.69x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is IPHA.US undervalued?
Graham numberThe Graham number of Innate Pharma cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Innate Pharma fundamental analysis
No fundamental analysis for Innate Pharma yet.
Innate Pharma stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that…
Full company profileInnate Pharma financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Innate Pharma annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 56.2M | 32.6M | 79.9M | 69.0M | 69.8M | 12.1M | 57.7M | 51.9M | 12.6M | 2.79M | 7.18M |
| Gross Profit | 7.53M | -34.4M | 10.3M | 23.8M | 20.1M | -22.3M | 6.01M | 5.62M | 12.6M | 2.79M | 48.2M |
| Operating Income | 7.57M | -40.0M | 5.15M | -27.1M | 1.08M | -47.8M | -57.4M | -12.7M | -51.6M | -53.4M | -94.0M |
| EBITDA | 10.8M | -35.6M | 12.5M | 18.1M | 57.9M | -43.2M | -12.3M | -1.84M | -46.9M | -43.6M | -99.1M |
| Net Income | 12.6M | -48.4M | 3.05M | -20.8M | -64.0M | -52.8M | -58.1M | -7.57M | -49.5M | -49.2M | -94.5M |
| EPS | 0.23 | -0.89 | 0.05 | -0.31 | -0.81 | -0.66 | -0.73 | -0.09 | -0.61 | -0.55 | -1.01 |
| Balance Sheet | |||||||||||
| Total Assets | 282M | 255M | 451M | 401M | 307M | 267M | 208M | 175M | 111M | 62.7M | 34.7M |
| Total Liabilities | 195M | 169M | 284M | 184M | 151M | 160M | 154M | 132M | 102M | 84.4M | 75.2M |
| Shareholders' Equity | 86.2M | 86.0M | 167M | 217M | 156M | 107M | 54.2M | 51.9M | 8.83M | -21.7M | -40.5M |
| Cash & Short-term Investments | 198M | 116M | 168M | 219M | 152M | 120M | 101M | 92.5M | 80.8M | 34.3M | 10.9M |
| Total Debt | 5.33M | 5.86M | 4.52M | 18.7M | 19.1M | 44.3M | 42.3M | 39.9M | 31.0M | 22.6M | 20.2M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -36.9M | -48.1M | -32.5M | 34.9M | -51.8M | -58.5M | -19.2M | -32.6M | -6.90M | -32.6M | -89.4M |
| Capital Expenditure | 9.39M | 6.03M | 1.43M | 65.4M | 11.3M | 1.33M | 1.12M | 351K | 391K | 2.35M | 353K |
| Free Cash Flow | -46.2M | -54.1M | -34.0M | -30.5M | -63.1M | -59.8M | -20.3M | -32.9M | -7.29M | -34.9M | -89.8M |
| Ratios | |||||||||||
| ROE | 14.7% | -56.3% | 1.8% | -9.5% | -41.0% | -49.2% | -107.3% | -14.6% | -560.0% | - | - |
| ROA | 4.5% | -19.0% | 0.7% | -5.2% | -20.8% | -19.7% | -28.0% | -4.3% | -44.5% | -78.4% | -272.2% |
| Net Profit Margin | 22.5% | -148.3% | 3.8% | -30.1% | -91.7% | -436.0% | -100.7% | -14.6% | -392.0% | -1,764.5% | -1,316.2% |
| Debt to Equity | 0.06x | 0.07x | 0.03x | 0.09x | 0.12x | 0.41x | 0.78x | 0.77x | 3.51x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Innate Pharma dividends
Innate Pharma has not paid dividends in the last 9 fiscal years.
Who owns Innate Pharma
- Insiders 1.40%
- Institutions 0.36%
- Public & others 98.24%
- Shares outstanding 112M
- Free float 68.9M
Top funds holding IPHA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Telescope Biotech Fund A FIL | 249K | 0.22% | 0.00% | Oct 2026 |
| Generali France PME ETI A | 126K | 0.11% | 0.00% | Jul 2026 |
Top institutions holding IPHA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Lion Point Capital, LP | 81.2K | 0.07% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 43.5K | 0.04% | 0.00% | Jun 2026 |
| SmartHarvest Portfolios, LLC | 23.8K | 0.02% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 15.1K | 0.01% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 12.4K | 0.01% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 10.3K | 0.01% | -76.23% | Jun 2026 |
| Rhumbline Advisers | 4.72K | 0.00% | 0.00% | Sep 2026 |
| UBS Group AG | 1.36K | 0.00% | +58.30% | Jun 2026 |
| GAMMA Investing LLC | 9.00 | 0.00% | -96.25% | Jun 2026 |
| Millennium Management LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Sageview Advisory Group LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Innate Pharma company profile
- Company name
- Innate Pharma
- Ticker
- IPHA.US
- Exchange
- USA Stocks
- Listed since
- Oct 17, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 120
- Fiscal year end
- December
- Address
- 117, Avenue de Luminy, Marseille, France, 13009
- Phone
- 33 4 30 30 30 30
- Website
- innate-pharma.com
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Innate Pharma management
10- Mr. Jonathan E. Dickinson B.Sc., M.B.A.CEO & Director · born 1968
- Mr. Yannis Morel Ph.D.Executive VP & COO · born 1973
- Dr. François Romagné Ph.D.Founder · born 1964
- Dr. Marc Bonneville Ph.D.Founder · born 1960
- Mr. Jean Jacques Fournié Ph.D.Founder
- Mr. Alessandro Moretta M.D., Ph.D.Founder
- Mr. Frederic Lombard M.B.A.Senior VP & CFO · born 1975
- Ms. Stephanie CornenVice President of Investor Relations, Communication & Commercial Strategy · born 1987
- Ms. Odile BelzunceVP, Chief of Compliance & Operations Officer and Interim Head of HR · born 1980
- Ms. Claire de Saint BlanquatVP of Legal & Corporate Affairs and Secretary of the Supervisory Board · born 1973